EXEL

Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023

Retrieved on: 
Sunday, October 22, 2023
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, Exelixis, National Institutes of Health, NCI, ESMO, Progression-free survival, Alliance for Clinical Trials in Oncology, Physician, Congress, PFS, European Society for Medical Oncology, Dana–Farber Cancer Institute, Glomus tumor, Data monitoring committee, Disease, NET, National Cancer Institute, Oncology, CET, NETS, EXEL, Pnet, Patient, Bangladesh Technical Education Board, DSMB, Pharmaceutical industry, Medical imaging, Carcinoid

Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from CABINET, a phase 3 pivotal trial evaluating cabozantinib (CABOMETYX®) compared with placebo in two cohorts of patients with previously treated neuroendocrine tumors: one cohort of patients with advanced pancreatic neuroendocrine tumors (pNET) and a second cohort of patients with advanced extra-pancreatic NET (epNET).

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from CABINET, a phase 3 pivotal trial evaluating cabozantinib (CABOMETYX®) compared with placebo in two cohorts of patients with previously treated neuroendocrine tumors: one cohort of patients with advanced pancreatic neuroendocrine tumors (pNET) and a second cohort of patients with advanced extra-pancreatic NET (epNET).
  • “Although progress has been made in recent years, there remains a critical need for new and effective therapies for patients with advanced neuroendocrine tumors.
  • Results from the CABINET study presented today at ESMO demonstrate that treatment with cabozantinib resulted in compelling improvements in PFS based both on local review and on independent blinded central radiology review.
  • The safety profile of cabozantinib observed in each cohort was consistent with its known safety profile; no new safety signals were identified.

Exelixis to Release Third Quarter 2023 Financial Results on Wednesday, November 1, 2023

Retrieved on: 
Wednesday, October 18, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, EXEL, Calendar, Webcast, PIN, Internet, Software, Broadcasting, Cryptocurrency, Exelixis

Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2023 financial results will be released on Wednesday, November 1, 2023 after the markets close.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2023 financial results will be released on Wednesday, November 1, 2023 after the markets close.
  • ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update.
  • To access the live webcast link, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading.
  • A webcast replay of the conference call will also be archived on www.exelixis.com for one year.

EXEL Industries: Daniel Tragus will be appointed CEO of EXEL Industries at the Board meeting on December 20th, 2023

Retrieved on: 
Monday, October 9, 2023
EXEL, ICAM, United Kingdom, Robotics, HEC Paris, Intec, COVID-19, Growth, Industrial property, Kremlin, Paris, Management, Devaux, Sames

Daniel Tragus will be appointed CEO of EXEL Industries at the Board meeting on December 20th, 2023

Key Points: 
  • Daniel Tragus will be appointed CEO of EXEL Industries at the Board meeting on December 20th, 2023
    Under the chairmanship of Mr. Patrick Ballu, EXEL Industries’ Board of Directors has chosen Daniel Tragus to succeed Yves Belegaud as Chief Executive Officer.
  • CEO of EXEL Industries since December 2019, Yves Belegaud gave notice of his intention to retire by the beginning of 2024.
  • An ICAM engineer and graduated with an Executive MBA from HEC Paris, Daniel Tragus has worked his whole career for different companies of the EXEL Industries Group.
  • He will take up the position of EXEL Industries’ Chief Executive Officer after the meeting of the Board of Directors, on December 20, 2023.

Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor

Retrieved on: 
Tuesday, September 12, 2023
Software, Research, Pharmaceutical, Oncology, Technology, Artificial Intelligence, Genetics, Clinical Trials, Science, Biotechnology, FDA, Health, DNA, HRR, Pharmacokinetics, Multimedia, Prostate, USP1, Protein, Patient, Translational research, Insilico Medicine, BRCA, PARP, IND, Safety, Breast cancer, EXEL, Pharmaceutical industry, Exelixis

Exelixis, Inc. (Nasdaq: EXEL) and Insilico Medicine (“Insilico”) today announced that the companies have entered into an exclusive license agreement granting Exelixis global rights to develop and commercialize ISM3091, a potentially best-in-class small molecule inhibitor of USP1, which has emerged as a synthetic lethal target in the context of BRCA-mutated tumors.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) and Insilico Medicine (“Insilico”) today announced that the companies have entered into an exclusive license agreement granting Exelixis global rights to develop and commercialize ISM3091, a potentially best-in-class small molecule inhibitor of USP1, which has emerged as a synthetic lethal target in the context of BRCA-mutated tumors.
  • View the full release here: https://www.businesswire.com/news/home/20230912041846/en/
    Under the terms of the agreement, Insilico granted Exelixis an exclusive, worldwide license to develop and commercialize ISM3091, and other USP1-targeting compounds, in exchange for an upfront payment to Insilico of $80 million anticipated in the third quarter 2023.
  • Insilico is also eligible to receive future development, commercial, and sales-based milestone payments, as well as tiered royalties on net sales.
  • On April 17, 2023, the FDA cleared the initial IND for ISM3091 for the treatment of patients with solid tumors.

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September

Retrieved on: 
Thursday, August 31, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, Calendar, Exelixis, Conference, EXEL, Software, Cryptocurrency

Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in September:

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in September:
    2023 Wells Fargo Healthcare Conference: Exelixis is scheduled to present at 11:00 a.m.
  • ET / 8:00 a.m. PT on Friday, September 8 in Everett, MA.
  • Morgan Stanley 21st Annual Global Healthcare Conference: Exelixis is scheduled to present at 1:35 p.m.
  • To access the webcast links, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading.

Exelixis Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors

Retrieved on: 
Thursday, August 24, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Glomus tumor, Medical Affairs Bureau, Disease, Senior, DSMB, Safety, Pnet, Alliance for Clinical Trials in Oncology, Incidence, National Cancer Institute, Data monitoring committee, HIV disease progression rates, Patient, Data, Pancreatic neuroendocrine tumor, Cancer, FDA, Exelixis, NCI, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Death, News, Food, EXEL, Dana–Farber Cancer Institute, Pharmaceutical industry, Carcinoid

CABINET is evaluating cabozantinib (CABOMETYX®) compared with placebo in patients with either advanced pancreatic neuroendocrine tumors (pNET) or advanced extra-pancreatic neuroendocrine tumors (also referred to as carcinoid tumors) who experienced progression after prior systemic therapy.

Key Points: 
  • CABINET is evaluating cabozantinib (CABOMETYX®) compared with placebo in patients with either advanced pancreatic neuroendocrine tumors (pNET) or advanced extra-pancreatic neuroendocrine tumors (also referred to as carcinoid tumors) who experienced progression after prior systemic therapy.
  • Cabozantinib substantially prolonged the time without disease progression or death in both of the trial’s cohorts.
  • CABINET is sponsored by the National Cancer Institute (NCI) and is led by The Alliance for Clinical Trials in Oncology.
  • “These promising findings from the CABINET trial, in which cabozantinib showed an efficacy benefit for patients with pancreatic and extra-pancreatic neuroendocrine tumors, are welcome news and show the potential for cabozantinib to address important unmet needs for this community.”

Exelixis Announces Appointment of Amy Peterson, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer

Retrieved on: 
Wednesday, August 23, 2023
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Talazoparib, Medical Affairs Bureau, Drug development, University, Internal medicine, Prostate cancer, Culture, IO, BeiGene, Thomas Jefferson University, Cancer, Investigational New Drug, Patient, FDA, Exelixis, Medivation, Northwestern Memorial Hospital, Breast cancer, EXEL, Pharmaceutical industry, Genentech

Exelixis, Inc. (Nasdaq: EXEL) today announced it has appointed Amy Peterson, M.D., its next Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) today announced it has appointed Amy Peterson, M.D., its next Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer.
  • She joins Exelixis as the company accelerates development of its product pipeline and builds on the success of its global cabozantinib oncology franchise.
  • Most recently, Dr. Peterson was at CytomX, first as Executive Vice President and Chief Development Officer and then as President and Chief Operating Officer.
  • “It’s a pleasure to welcome Dr. Amy Peterson to Exelixis as the company’s next Chief Medical Officer.

Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer

Retrieved on: 
Monday, August 21, 2023
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Oncology, Men, Research, Consumer, Science, Clinical Trials, IPN, Medical Affairs Bureau, University, ADR, Progression-free survival, Prostate cancer, OS, Cancer, Immunotherapy, PFS, University of Utah, Huntsman Cancer Institute, Professor, Patient, Exelixis, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, EXEL, Medical imaging, Pharmaceutical industry, Ipsen, Euronext

CONTACT-02 is evaluating cabozantinib (CABOMETYX®) in combination with atezolizumab compared with a second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) and measurable soft tissue disease who have been previously treated with one novel hormonal therapy.

Key Points: 
  • CONTACT-02 is evaluating cabozantinib (CABOMETYX®) in combination with atezolizumab compared with a second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) and measurable soft tissue disease who have been previously treated with one novel hormonal therapy.
  • Therefore, the trial will continue to the next analysis of OS as planned.
  • The safety profile of the combination of cabozantinib and atezolizumab was consistent with the known safety profiles for each single medicine, and no new safety signals were identified with the combination.
  • “These results represent the first positive phase 3 data of its kind for a tyrosine kinase inhibitor and immunotherapy combination in this indication.

Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer

Retrieved on: 
Monday, August 21, 2023
IPN, Medical Affairs Bureau, University, PARIS, ADR, Progression-free survival, Prostate cancer, OS, Cancer, Immunotherapy, PFS, University of Utah, Huntsman Cancer Institute, Professor, Patient, Exelixis, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, EXEL, Medical imaging, Pharmaceutical industry, Ipsen, Euronext, Research

CONTACT-02 is evaluating cabozantinib (CABOMETYX®) in combination with atezolizumab compared with a second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) and measurable soft tissue disease who have been previously treated with one novel hormonal therapy.

Key Points: 
  • CONTACT-02 is evaluating cabozantinib (CABOMETYX®) in combination with atezolizumab compared with a second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) and measurable soft tissue disease who have been previously treated with one novel hormonal therapy.
  • Therefore, the trial will continue to the next analysis of OS as planned.
  • The safety profile of the combination of cabozantinib and atezolizumab was consistent with the known safety profiles for each single medicine, and no new safety signals were identified with the combination.
  • “These results represent the first positive phase 3 data of its kind for a tyrosine kinase inhibitor and immunotherapy combination in this indication.

Exelixis Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, August 1, 2023
General Health, Public Relations, Investor Relations, Health, Communications, Oncology, Table, Prostate cancer, Takeda Pharmaceutical Company, Clinical trial, EXEL, Cancer, GAAP, Research, Patient, Ipilimumab, Collaboration, Survival analysis, Total, Nivolumab, Renal cell carcinoma, Pharmaceutical industry, Reinsurance, Insurance, Exelixis

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the second quarter of 2023 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the second quarter of 2023 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones.
  • “In the second quarter of 2023, the Exelixis team continued to make steady progress both on our commercial business and our rapidly advancing pipeline,” said Michael M. Morrissey, Ph.D., President and Chief Executive Officer, Exelixis.
  • Exelixis believes that the presentation of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors.
  • Exelixis is maintaining the previously provided financial guidance for fiscal year 2023: